Management of Hypertension in Nephrotic Syndrome with Acute Kidney Injury

Initial Evaluation and Management

In patients with nephrotic syndrome and acute kidney injury, the American College of Cardiology recommends not initiating ACE inhibitors/ARBs immediately; instead, stabilize volume with loop diuretics and control blood pressure with calcium channel blockers, delaying ACE inhibitors/ARBs until renal function stabilizes, especially if minimal change disease is suspected 1, 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest identifying if the nephrotic syndrome is of abrupt onset: if presentation is abrupt (days to weeks), suspect minimal change disease and avoid ACE inhibitors/ARBs as they can cause additional acute kidney injury in this context 1, 2, 3, 4

The European Society of Cardiology recommends starting loop diuretics (furosemide) as first-line therapy, with dosing twice daily, to manage volume and edema 2, 3, 4
Increase the dose of loop diuretic until clinically significant diuresis is achieved or until the maximum effective dose is reached 2, 3, 4
If there is resistance to furosemide, consider switching to bumetanide or torasemida due to better oral bioavailability 2, 3, 4
For resistant edema, combine loop diuretics with thiazides in high doses for sequential blockade of the nephron 1, 2, 3

The American Heart Association recommends introducing ACE inhibitors/ARBs after stabilization of renal function, with criteria including stable or improving serum creatinine for at least 5-7 days, and ruling out minimal change disease if possible 1, 2, 3
Start with low doses of ACE inhibitors (enalapril 2.5 mg/day) or ARBs (losartan 25 mg/day) and gradually titrate up to the maximum tolerated or allowed dose, not just until blood pressure control is achieved 1, 2, 5, 6

The American College of Cardiology recommends a blood pressure target of <120 mmHg using standardized office measurement, with a target proteinuria reduction <1 g/day, not just blood pressure control 1, 5, 2, 3, 4, 6, 7
Consider adding calcium channel blockers if blood pressure is not controlled, and consider mineralocorticoid receptor antagonists for resistant proteinuria (monitoring for hyperkalemia) 1, 5
Lifestyle modifications, including sodium restriction <2.0 g/day, weight normalization if BMI >25 kg/m², smoking cessation, and regular exercise, are synergistic with medication therapy 1, 5, 2, 4, 6, 7

The KDIGO guidelines recommend that ACE inhibitors and ARBs are interchangeable, and if one class is not tolerated, the other should be substituted, as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 8, 9
The KDIGO guidelines do not recommend one ARB over another for nephrotic syndrome, emphasizing the importance of choosing based on the underlying cause, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 8, 9
For minimal change disease (MCD) with first episode nephrotic syndrome, ARBs should not be used in normotensive patients solely to lower proteinuria, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 10

Losartan has the broadest evidence base across different causes of nephrotic syndrome, including diabetic nephropathy, IgA nephropathy, secondary amyloidosis, membranous nephropathy, and steroid-resistant nephrotic syndrome in children, as reported in studies published in Kidney International 10, 11

The American Diabetes Association and the National Kidney Foundation recommend monitoring closely for hyperkalemia, especially with advanced renal insufficiency or hyporeninemic hypoaldosteronism, when using ARBs, as stated in guidelines from the American Diabetes Association and the National Kidney Foundation 8, 9
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend checking serum potassium levels regularly when using ARBs, to prevent hyperkalemia 8

The American College of Cardiology recommends choosing losartan as the first-line ARB, due to its extensive evidence base across disease states, as stated in guidelines from the American College of Cardiology 10, 11
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) recommends starting with a low dose of losartan (25-50 mg/day) and titrating to the optimal dose (100 mg/day) for most patients, to achieve maximum renoprotective benefits, as reported in guidelines from the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) 8, 9